"We Make Less Than KRW 10,000 Selling Them"... As More People Buy Them in Japan, Obesity Drugs Sell Below Supply Prices
Mounjaro Sells for KRW 6,000 Below Supply Price
Wegovy Price Falls by KRW 11,000 in Two Weeks
"Fierce Price Competition... Concerns Over Indiscriminate Prescribing"
With the import of obesity medications prescribed in Japan now permitted, the prices of Mounjaro and Wegovy have fallen below pharmaceutical companies' supply prices, drawing attention. In effect, the "price floor" for pharmacy sales has collapsed. Pharmacies are locked in a fierce price war, undercutting one another by as little as 1,000 won. As more people may seek prescriptions and purchase obesity medications in Japan, where prices are far lower than in Korea, this competition is expected to intensify further.
With the import of obesity medications prescribed in Japan now permitted, the prices of Mounjaro and Wegovy have fallen below pharmaceutical companies' supply prices. The image is AI-generated for illustrative purposes.
View original imageAccording to Dr. Now, a telemedicine platform, on November 16, the lowest price at a pharmacy in Seoul for four 2.5 mg Mounjaro pens (a four-week supply) is 272,000 won. Lilly Korea set its supply price at 278,066 won when it launched the drug in August 2025, making the price patients pay at pharmacies 6,066 won below the supply price. The lowest price for one 0.25 mg Wegovy pen (a four-week supply) is 212,000 won. Wegovy's supply price is reportedly around 216,000 won for the 0.25 mg dose.
The price floor for Mounjaro and Wegovy continues to fall. In August 2026, the lowest price for four 2.5 mg Mounjaro pens was 274,500 won. It was already 3,566 won below the supply price at the time, but fell by another 2,500 won over the next three months to 272,000 won. Until the end of October, when the locally made obesity drug Epe was launched, the lowest price for one 0.25 mg Wegovy pen was 223,000 won, about 8,000 won above the supply price. In just over two weeks, the price dropped by 11,000 won to 212,000 won, below the supply price.
Pharmacies can sell these drugs for less than the supply price because their actual purchase price, known as the "acquisition price," is lower. The supply price is a benchmark set by the pharmaceutical company. The acquisition price is negotiated separately each time a pharmacy purchases from a wholesaler, depending on the order volume and payment terms. Pharmacist A, who runs a pharmacy in Seoul, said, "The terms differ for a pharmacy that buys 10 units and one that buys 100. The larger the pharmacy, the more likely it is to purchase the drugs below the supply price." Mounjaro and Wegovy are non-reimbursed medications not covered by national health insurance, so there is no government-set price ceiling or floor.
Industry sources estimate that pharmacies currently make less than 10,000 won from selling Mounjaro and Wegovy. Pharmacist B, who works at another pharmacy in Seoul, said, "With the profit margin shrinking this much, pharmacies are slashing prices in increments of 1,000 or 2,000 won and engaging in a fierce price war, advertising the lowest prices to attract patients." The pharmacist added, "The competition to lower drug prices is not limited to pharmacies; it also appears to be affecting prices for drugs purchased directly by hospitals and sold to patients."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
As consultation fees and drug prices fall together, concerns are also growing that this cutthroat, high-volume pricing competition could lead to indiscriminate prescribing. A professor at a university hospital said, "Obesity treatments in the glucagon-like peptide-1 (GLP-1) class, such as Wegovy and Mounjaro, are prescription drugs, and it is important to prescribe them with each patient's health condition and long-term treatment plan in mind." The professor added, "As the number of patients receiving obesity treatments rises, intensifying price competition could lead to more practices that prioritize attracting patients and boosting revenue over these prescribing principles."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.